Lazard Asset Management
PTCT icon

Lazard Asset Management’s PTC Therapeutics PTCT Stock Holding History

Lazard Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.77M Buy
25,988
+2,788
+12% +$197K ﹤0.01% 955
2025
Q4 		$1.76M Buy
23,200
+4,255
+22% +$309K ﹤0.01% 921
2025
Q3 		$1.16M Sell
18,945
-2,881
-13% -$150K ﹤0.01% 1095
2025
Q2 		$1.06M Sell
21,826
-278
-1% -$13.2K ﹤0.01% 1281
2025
Q1 		$1.12M Sell
22,104
-23,543
-52% -$1.17M ﹤0.01% 1179
2024
Q4 		$2.06M Buy
45,647
+34,069
+294% +$1.46M ﹤0.01% 872
2024
Q3 		$428K Sell
11,578
-7,082
-38% -$237K ﹤0.01% 1405
2024
Q2 		$568K Buy
18,660
+12,156
+187% +$394K ﹤0.01% 1158
2024
Q1 		$188K Buy
6,504
+4,741
+269% +$133K ﹤0.01% 1317
2023
Q4 		$47K Sell
1,763
-3,637
-67% -$83.2K ﹤0.01% 1904
2023
Q3 		$120K Buy
5,400
+1,063
+25% +$39.5K ﹤0.01% 1562
2023
Q2 		$175K Buy
4,337
+3,017
+229% +$148K ﹤0.01% 1383
2023
Q1 		$63K Sell
1,320
-1,158
-47% -$52.9K ﹤0.01% 1722
2022
Q4 		$94K Buy
2,478
+1,326
+115% +$55.1K ﹤0.01% 1554
2022
Q3 		$57K Buy
+1,152
New +$56.4K ﹤0.01% 1741
2022
Q2 		– Sell
-25,192
Closed -$939K – 2537
2022
Q1 		$939K Buy
25,192
+23,250
+1,197% +$896K ﹤0.01% 1009
2021
Q4 		$77K Buy
+1,942
New +$74.3K ﹤0.01% 1543
2021
Q3 		– Sell
-282
Closed -$11K – 2261
2021
Q2 		$11K Sell
282
-2,931
-91% -$126K ﹤0.01% 1895
2021
Q1 		$152K Sell
3,213
-6,821
-68% -$405K ﹤0.01% 1143
2020
Q4 		$612K Buy
+10,034
New +$591K ﹤0.01% 950
2020
Q2 		– Sell
-1,580
Closed -$70K – 1757
2020
Q1 		$70K Buy
+1,580
New +$79.6K ﹤0.01% 1081
2019
Q4 		– Sell
-346
Closed -$11K – 1639
2019
Q3 		$11K Buy
+346
New +$15.1K ﹤0.01% 1294
2016
Q1 		– Sell
-9,275
Closed -$300K – 1094
2015
Q4 		$300K Sell
9,275
-6,234
-40% -$183K ﹤0.01% 769
2015
Q3 		$414K Buy
+15,509
New +$663K ﹤0.01% 718

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Lazard Asset Management's PTCT Position: Q1 2026 in Review

Lazard Asset Management increased its PTC Therapeutics (PTCT) stake by 12% in Q1 2026, buying an estimated $197K and bringing the position to 25,988 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #955.

Lazard Asset Management first reported a position in PTCT in Q3 2015 and has held it in 24 quarters since. The position peaked at $2.06M in Q4 2024. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Lazard Asset Management held 25,988 shares of PTC Therapeutics worth $1.77M as of Q1 2026.
  • Lazard Asset Management bought 2,788 PTC Therapeutics shares in Q1 2026, an estimated $197K.
  • PTC Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #955 holding.
  • Lazard Asset Management first reported a position in PTC Therapeutics in Q3 2015 and has held it in 24 quarters since.
  • Lazard Asset Management's PTC Therapeutics position peaked at $2.06M in Q4 2024.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.